What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves’ disease

Salman Razvi, Bijay Vaidya, Petros Perros and Simon H S Pearce

1Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK, 2Department of Endocrinology and Diabetes, Royal Devon and Exeter Hospital, Exeter, UK, 3Department of Endocrinology, Freeman Hospital, Newcastle upon Tyne, UK and 4Institute of Human Genetics & School of Clinical Medical Sciences, University of Newcastle, Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK

(Correspondence should be addressed to S Pearce at the Institute of Human Genetics, University of Newcastle, UK; Email: s.h.s.pearce@ncl.ac.uk)

Abstract

Block-replace and titration antithyroid drug regimens both give similar rates of medium- to long-term remission of hyperthyroid Graves’ disease. Recent meta-analysis, however, has suggested that titration regimens may be preferable owing to a higher rate of adverse events seen in the block-replace arms of published comparative studies. This article critically re-evaluates the evidence upon which these meta-analyses were based. We suggest that there is little objective evidence that is pertinent to current clinical practice to separate block-replace from titration antithyroid drug regimens and that both remain satisfactory approaches to the medical management of hyperthyroid Graves’ disease.

Background

It is imperative that physicians look carefully at the evidence that guides their clinical practice. This evidence may be derived from many sources, ranging from a rigorous, randomised controlled trial (RCT), through to the reported experiences of respected colleagues. Individual RCTs are rarely identical in terms of protocol, characteristics of enrolled patient groups or clinical outcomes. So where several RCTs have been performed, meta-analysis has also become a common means to assess the average benefit or hazard that a practitioner might expect from using a treatment. Such meta-analysis should represent the best possible summation of the evidence and may be appropriately endorsed by publication in an authoritative journal or by being included in a peer-reviewed collection of evidence-based analysis such as the Cochrane Library Collection. These works are important benchmarks for good practice and in a world where there is increasing external regulation of medical care, such meta-analyses are taken as gold-standard evidence by those commissioning healthcare and thus may even influence the range of treatments that are available in managed care settings. They may also form the basis for legal representations following an adverse outcome of care. Thus, it is critical that meta-analyses are conducted rigorously, and that their results are interpreted in a fashion appropriate to the evidence base. In this paper we comment on the interpretation of the widely published meta-analyses of trials of antithyroid drug treatment for Graves’ disease.

Analysis

In the UK, it is common practice to initiate drug therapy of hyperthyroid Graves’ disease with 40 mg daily of carbimazole. In countries where methimazole is available, 30 mg is the frequent daily starting dose. Although Abrahams and colleagues comment that methimazole and carbimazole have ‘dose equivalence’, in fact the compounds have molar dose equivalence. However, as carbimazole has a higher molecular mass than methimazole (186 vs 114) the administered doses are not equivalent, with 6.1 mg methimazole having the same in vivo effect as about 10 mg carbimazole. After 6–8 weeks of treatment with methimazole 30 mg daily or carbimazole 40 mg daily, the majority of subjects with hyperthyroid Graves’ disease have become euthyroid (as judged by normal serum-free thyroid hormone concentrations). At this stage treatment can be continued either with a block-replace or a titrated dose antithyroid drug regimen. For a block-replace regimen, a replacement dose of thyroxine is added, and the antithyroid drug is continued in an unchanged dose. In a titrated dose regimen, the thionamide dose is...
reduced, and the endogenous production of thyroxine is maintained from the partial block to thyroid hormone synthesis. It is clear that there is little to choose between titrated and block-replace antithyroid drug regimens in terms of long-term outcome of Graves’ disease. Twenty-four months after stopping treatment, both methods leave approximately 50% of subjects in medium- to long-term remission (2, 3, 6–8). Thus, the evidence cited by Abrahams and colleagues to favour titrated antithyroid drug regimens over block-replace regimens comes exclusively from the higher rate of adverse events found in the block-replace arms of the trials examined by the meta-analysis. We would like to comment on several features of this analysis, focusing initially on these adverse events.

Some of the adverse effects of thionamide drug treatment may be regarded as minor, such as rash or episodes of hypothyroidism on treatment, which are inconvenient for the patient (9). Nonetheless, these minor adverse events may lead to withdrawal of drug therapy, and hence result in a failure of medical treatment. However, it is the serious adverse event of agranulocytosis that is of primary concern, and there is already good evidence that the prevalence of this feared complication is dependent upon the dose of antithyroid drug (10, 11). For instance, Wiberg and Nuttall’s study of 25 patients with hyperthyroidism treated with methimazole 120 mg daily found that three (12%) developed neutropenic fever or agranulocytosis (10). Similarly, in the randomised study of Grebe et al., which is included in the meta-analysis, 2 of 17 Graves’ patients (12%) treated with carbimazole 100 mg daily for 6 months also developed agranulocytosis (11). These high rates of neutrophil dyscrasia observed with high-dose thionamide treatment need to be compared with a prevalence of about 0.4% from a prospectively monitored patient cohort on conventional antithyroid drug doses (12). In the meta-analysis, seven studies were used to provide evidence of the adverse effects of the antithyroid drug regimens (the publications of Reinwein and Benker report the same clinical cohort) (8, 11, 13–18). However, six of these seven had used thionamide doses in the block-replace arm that are significantly higher than would now represent conventional clinical practice (Table 1). Indeed, the stated aim of several of these studies was to determine whether improved remission rates could be obtained from higher dose treatment, not to compare the tolerability of the two regimens (11, 14). Thus only one out of the seven studies analysed are relevant to current clinical practice in employing a conventional starting dose of thionamide for a block-replace regimen (16). While it is undoubtedly true that collectively these studies showed a higher rate of adverse events in the block-replace arms, it is also clear that these studies are not representative of current mainstream clinical practice, as only in exceptional circumstances (e.g. cardiac compromise, thyrotoxic storm) would most patients be started on more than 40 mg carbimazole or equivalent. Therefore, we feel that the conclusion that a titrated antithyroid drug regimen should be considered the optimal first-line drug treatment for Graves’ disease cannot be supported on this basis.

In an attempt to analyse this issue further, we re-examined the original publications and reconsidered some of the analyses. We were surprised to find that the data extracted from one of the original publications had been misrepresented. In the study of Edmonds & Tellez (13), all 70 Graves’ disease patients were treated for an initial period of 4 weeks with carbimazole 60 mg daily, and then the treatment arms diverged to block-replace or titration regimens. Nine patients with rash were reported during the initial 4 week period, without details of their treatment allocation in the original report. During the rest of the study, two patients on block-replace and one on titrated dose carbimazole were reported to have developed rash (12 episodes of rash in total). In the meta-analysis (2, 3), only nine episodes of rash are included and all are categorised as having occurred on block-replace producing the most extreme deviation from statistical normality of all the studies. Repeating the meta-analysis using the amended data on rash from this study (seven episodes on block-replace vs five with titration; C J Edmonds, personal communication) subtly alters the conclusions. Indeed, if these revised data are included, and we exclude the two studies that are clearly ‘outliers’ to current practice in terms of the dose of thionamide used (those using carbimazole 100 mg or methimazole 60 mg daily (11, 14)), there is no significant difference in the rate

Table 1 Studies comparing the two treatment regimens of antithyroid medication and their doses.

<table>
<thead>
<tr>
<th>Author; year</th>
<th>Drug dose in block-replace arm (mg/day)</th>
<th>Carbimazole dose equivalent (mg/day)*</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edmonds &amp; Tellez; 1994</td>
<td>Carbimazole 60</td>
<td>–</td>
<td>13</td>
</tr>
<tr>
<td>Leclere; 1994</td>
<td>Carbimazole 60</td>
<td>–</td>
<td>15</td>
</tr>
<tr>
<td>Jorde et al.; 1995</td>
<td>Methimazole 60</td>
<td>98</td>
<td>14</td>
</tr>
<tr>
<td>Wilson et al.; 1996</td>
<td>Carbimazole 60</td>
<td>–</td>
<td>17</td>
</tr>
<tr>
<td>Grebe et al.; 1998</td>
<td>Carbimazole 100</td>
<td>–</td>
<td>11</td>
</tr>
<tr>
<td>Benker et al.; 1998</td>
<td>Methimazole 40</td>
<td>66</td>
<td>8</td>
</tr>
<tr>
<td>Nedrebo et al.; 2002</td>
<td>Carbimazole 29†</td>
<td>–</td>
<td>16</td>
</tr>
</tbody>
</table>

*Based on dose equivalence reported by Jansen et al. (5).
†Mean daily dose.

www.eje-online.org
of rash between the two groups (odds ratio 1.52, 5–95% confidence intervals 0.97–2.38) (Fig. 1). This suggests that the benefit of the titration regimen over block-replace for the adverse event of rash may be marginal at currently employed doses.

Concerning the important adverse event of agranulocytosis, there were 12 episodes reported from five studies, encompassing a total of 943 patients. Of these 12 episodes, four (three block-replace, one titrated) were reported in the 93 patients in the two highest dose studies; those using carbimazole 100 mg or methimazole 60 mg daily (11, 14). Overall, there was no significant difference in the rate between either regimen; however, it needs to be borne in mind that these studies were not of sufficient power to detect a real difference in agranulocytosis rate (around 30% collective power to detect a true doubling of agranulocytosis events at p=0.05, given the numbers of patients). Furthermore, the peak time for agranulocytosis is during the 4th to 6th week of antithyroid drug therapy (19), at a time when the majority of subjects will be on the same dose of antithyroid drug, whichever regimen the physician intends to use.

Thus, under close scrutiny, the evidence to favour titration antithyroid regimens over block-replace owing to differences in adverse event rate seems unconvincing, particularly so given the more modest doses of these compounds currently employed in block-replace regimens. The dose of antithyroid drug used in the studies that were meta-analysed is not representative of everyday practice. Other factors that were not directly addressed in the meta-analysis may also be relevant. First, prolonged periods of mild to moderate hypothyroidism can be considered a significant adverse event related to titrated antithyroid drug regimens, which rarely occurs during block-replace treatment. The Cochrane review (2) acknowledges that no trial provides any data about this predictable side-effect, which may be an important factor in the progression of thyroid eye disease (20) and possibly for future vascular risk (21). Furthermore, hypothyroidism may contribute to significant weight gain, which is subsequently difficult to reverse. In addition, about 20% of subjects with Graves’ hyperthyroidism may have antibodies directed against the thyroid-stimulating hormone (TSH) receptor that have blocking effects, as well as the usual stimulatory antibodies. In these subjects, spontaneous fluctuations in the degree of antibody-induced thyroid stimulation may be difficult to control with a titrated regimen, whereas such fluctuations are rarely observed in subjects on block-replace regimens. Although there are no studies comparing cost effectiveness, it is our impression that patients on a block-replace regimen require less frequent clinical and biochemical monitoring of thyroid function than a titrated dose regimen. In the UK, the cost to the NHS for a year of titration dose regimen with carbimazole (40 mg for 6 weeks, followed by 20 mg for 8 weeks, 10 mg for 12 weeks and eventually 5 mg for 26 weeks) is £28.70 compared with £105.85 for the same duration of block-replacement 40 mg carbimazole and 100 µg thyroxine (22). It is likely that the latter regimen will be cheaper overall, since additional clinic visits and biochemical testing will more than offset the extra drug costs.

Conclusion

In summary, we suggest that block-replace antithyroid drug regimens, using modest daily doses of antithyroid agents (i.e. carbimazole 40 mg daily or equivalent) remain an excellent approach to managing Graves’ disease. For patients with thyroid eye disease, or those at risk of this complication, for those with fluctuant thyroid function during treatment and for those in
whom frequent blood testing is unavailable or undesirable, we feel that block-replace regimens may have significant advantages as medical therapy for hyperthyroid Graves’ disease. We support the other recommendations of the meta-analysis, in particular that radiiodine therapy should be discussed at an early stage with subjects who have moderate to severe hyperthyroidism without thyroid eye disease. We also agree that adequately powered trials of titration and block-replace regimens, with commonly used doses of antithyroid drug, would provide a better evidence base for decision making.

Acknowledgements

We are grateful to Dr C J Edmonds for sharing data with us. We understand that an amendment to the Cochrane review (2) will be undertaken at the next online revision (P Abraham, personal communication).

References


Received 1 March 2006
Accepted 21 March 2006